{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:18:13Z","timestamp":1790421493030,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1124\/jpet.114.218651","type":"journal-article","created":{"date-parts":[[2014,10,3]],"date-time":"2014-10-03T02:19:54Z","timestamp":1412302794000},"page":"642-653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Neurophysiologic and Antipsychotic Profiles of TASP0433864, a Novel Positive Allosteric Modulator of Metabotropic Glutamate 2 Receptor"],"prefix":"10.1016","volume":"351","author":[{"given":"Tetsuaki","family":"Hiyoshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Marumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohiko","family":"Hikichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasumitsu","family":"Tomishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Tamita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akito","family":"Yasuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Karasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Chaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.114.218651_bib1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1124\/mol.107.035170","article-title":"A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis","volume":"72","author":"Benneyworth","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.114.218651_bib2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1176\/ajp.154.6.805","article-title":"Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers","volume":"154","author":"Breier","year":"1997","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.114.218651_bib3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/0006-8993(94)90523-1","article-title":"The effects of methamphetamine and cocaine on motor behavior and extracellular dopamine in the ventral striatum of Lewis versus Fischer 344 rats","volume":"668","author":"Camp","year":"1994","journal-title":"Brain Res"},{"key":"10.1124\/jpet.114.218651_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0022-3565(24)35084-0","article-title":"The metabotropic glutamate 2\/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats","volume":"291","author":"Cartmell","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.218651_bib5","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1046\/j.1471-4159.2000.0750889.x","article-title":"Regulation of neurotransmitter release by metabotropic glutamate receptors","volume":"75","author":"Cartmell","year":"2000","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.114.218651_bib6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejphar.2009.12.041","article-title":"Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia","volume":"639","author":"Chaki","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.114.218651_bib7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1124\/jpet.110.173880","article-title":"Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2\/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals","volume":"336","author":"Chin","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.218651_bib8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev.pharmtox.37.1.205","article-title":"Pharmacology and functions of metabotropic glutamate receptors","volume":"37","author":"Conn","year":"1997","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/jpet.114.218651_bib9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-010-2052-z","article-title":"Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2\/3 receptor agonist","volume":"214","author":"Dedeurwaerdere","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.114.218651_bib10","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/sj.npp.1301531","article-title":"Efficacy and tolerability of an mGlu2\/3 agonist in the treatment of generalized anxiety disorder","volume":"33","author":"Dunayevich","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.114.218651_bib11","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.neuropharm.2011.06.007","article-title":"Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia","volume":"62","author":"Fell","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.114.218651_bib12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.108.136861","article-title":"Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2\/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039)","volume":"326","author":"Fell","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.218651_bib13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/jpet.110.172957","volume":"336","author":"Fell","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.218651_bib14","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1517\/13543770903045009","article-title":"Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia","volume":"19","author":"Fraley","year":"2009","journal-title":"Expert Opin Ther Pat"},{"key":"10.1124\/jpet.114.218651_bib15","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/jpet.105.091074","article-title":"A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2\/3 receptor agonist in mouse models predictive of antipsychotic activity","volume":"315","author":"Galici","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.218651_bib16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1124\/jpet.106.102046","article-title":"Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice","volume":"318","author":"Galici","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.218651_bib17","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1038\/sj.npp.1301547","article-title":"Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine","volume":"33","author":"Gozzi","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.114.218651_bib18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s00213-003-1444-8","article-title":"Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans","volume":"168","author":"Grillon","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.114.218651_bib19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.brainresrev.2008.07.006","article-title":"The acute effects of NMDA antagonism: from the rodent to the human brain","volume":"60","author":"Gunduz-Bruce","year":"2009","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1124\/jpet.114.218651_bib20","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.neuropharm.2014.05.037","article-title":"Differential effects of NMDA receptor antagonists at lower and higher doses on basal gamma band oscillation power in rat cortical electroencephalograms","volume":"85","author":"Hiyoshi","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.114.218651_bib21","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1152\/jn.00875.2004","article-title":"Activation of metabotropic glutamate 2\/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats","volume":"93","author":"Homayoun","year":"2005","journal-title":"J Neurophysiol"},{"key":"10.1124\/jpet.114.218651_bib22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00213-004-2099-9","article-title":"Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)","volume":"179","author":"Johnson","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.114.218651_bib23","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1017\/S1461145711000848","article-title":"Acute administration of typical and atypical antipsychotics reduces EEG \u03b3 power, but only the preclinical compound LY379268 reduces the ketamine-induced rise in \u03b3 power","volume":"15","author":"Jones","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1124\/jpet.114.218651_bib24","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00213-004-2025-1","article-title":"Effects of a metabotropic glutamate(2\/3) receptor agonist (LY544344\/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results","volume":"179","author":"Kellner","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.114.218651_bib25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0028-3908(00)00118-0","article-title":"Activity-dependent presynaptic autoinhibition by group II metabotropic glutamate receptors at the perforant path inputs to the dentate gyrus and CA1","volume":"40","author":"Kew","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.114.218651_bib26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00213-005-2200-z","article-title":"Ionotropic and metabotropic glutamate receptor structure and pharmacology","volume":"179","author":"Kew","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.114.218651_bib27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0028-3908(02)00084-9","article-title":"Differential regulation of synaptic transmission by mGlu2 and mGlu3 at the perforant path inputs to the dentate gyrus and CA1 revealed in mGlu2 -\/- mice","volume":"43","author":"Kew","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.114.218651_bib28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0014-2999(98)00526-3","article-title":"Presynaptic inhibitory action of the group II metabotropic glutamate receptor agonists, LY354740 and DCG-IV","volume":"356","author":"Kilbride","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.114.218651_bib29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00213-004-1982-8","article-title":"Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects","volume":"179","author":"Krystal","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.114.218651_bib30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00213-003-1582-z","article-title":"NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development","volume":"169","author":"Krystal","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.114.218651_bib31","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1196\/annals.1300.063","article-title":"Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment","volume":"1003","author":"Laruelle","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1124\/jpet.114.218651_bib32","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1124\/jpet.113.204990","article-title":"Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782","volume":"346","author":"Lavreysen","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.218651_bib33","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0306-4522(02)00652-8","article-title":"Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268","volume":"117","author":"Lorrain","year":"2003","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.114.218651_bib34","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0893-133X(99)00127-X","article-title":"Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice","volume":"22","author":"Miyamoto","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.114.218651_bib35","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.281.5381.1349","article-title":"Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats","volume":"281","author":"Moghaddam","year":"1998","journal-title":"Science"},{"key":"10.1124\/jpet.114.218651_bib36","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.114.218651_bib37","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1021\/jm9606756","volume":"40","author":"Monn","year":"1997","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.114.218651_bib38","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1126\/science.1329206","article-title":"Molecular diversity of glutamate receptors and implications for brain function","volume":"258","author":"Nakanishi","year":"1992","journal-title":"Science"},{"key":"10.1124\/jpet.114.218651_bib39","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1021\/jm000346k","article-title":"Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists","volume":"43","author":"Nakazato","year":"2000","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.114.218651_bib40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0304-3940(95)12248-6","article-title":"Pre- and postsynaptic localization of a metabotropic glutamate receptor, mGluR2, in the rat brain: an immunohistochemical study with a monoclonal antibody","volume":"202","author":"Neki","year":"1996","journal-title":"Neurosci Lett"},{"key":"10.1124\/jpet.114.218651_bib41","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.neuropharm.2010.10.022","article-title":"Metabotropic glutamate receptors: from the workbench to the bedside","volume":"60","author":"Nicoletti","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.114.218651_bib42","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nm1632","article-title":"Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial","volume":"13","author":"Patil","year":"2007","journal-title":"Nat Med"},{"key":"10.1124\/jpet.114.218651_bib43","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2007"},{"key":"10.1124\/jpet.114.218651_bib44","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.biopsych.2007.10.006","article-title":"N-methyl d-aspartate receptor antagonists ketamine and MK-801 induce wake-related aberrant gamma oscillations in the rat neocortex","volume":"63","author":"Pinault","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.114.218651_bib45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-007-0758-3","article-title":"In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2\/3 receptor agonist LY404039 in animal models of psychiatric disorders","volume":"193","author":"Rorick-Kehn","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.114.218651_bib46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ab.2011.01.022","article-title":"An enzymatic photometric assay for 2-deoxyglucose uptake in insulin-responsive tissues and 3T3-L1 adipocytes","volume":"412","author":"Saito","year":"2011","journal-title":"Anal Biochem"},{"key":"10.1124\/jpet.114.218651_bib47","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/mp.2013.130","article-title":"Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects","volume":"19","author":"Sanacora","year":"2014","journal-title":"Mol Psychiatry"},{"key":"10.1124\/jpet.114.218651_bib48","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0028-3908(99)00092-1","article-title":"Pharmacological agents acting at subtypes of metabotropic glutamate receptors","volume":"38","author":"Schoepp","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.114.218651_bib49","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/1025389031000146773","article-title":"LY354740, an mGlu2\/3 receptor agonist as a novel approach to treat anxiety\/stress","volume":"6","author":"Schoepp","year":"2003","journal-title":"Stress"},{"key":"10.1124\/jpet.114.218651_bib50","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1523\/JNEUROSCI.17-19-07503.1997","article-title":"Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus","volume":"17","author":"Shigemoto","year":"1997","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.114.218651_bib51","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00213-002-1288-7","article-title":"Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats","volume":"165","author":"Shoblock","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.114.218651_bib52","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0091-3057(97)00043-9","article-title":"Differential behavioral responses to dopaminergic stimulation of nucleus accumbens subregions in the rat","volume":"58","author":"Swanson","year":"1997","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.114.218651_bib53","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0306-4522(01)00305-0","article-title":"Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites","volume":"106","author":"Tamaru","year":"2001","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.114.218651_bib54","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s11064-005-8390-2","article-title":"Effects of monoamine oxidase inhibitors on methamphetamine-induced stereotypy in mice and rats","volume":"30","author":"Tatsuta","year":"2005","journal-title":"Neurochem Res"},{"key":"10.1124\/jpet.114.218651_bib55","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0306-4522(99)00158-X","article-title":"High versus low reactivity to a novel environment: behavioural, pharmacological and neurochemical assessments","volume":"93","author":"Thiel","year":"1999","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.114.218651_bib56","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00213-007-0974-x","article-title":"The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2\/3 agonist, LY379268, in mouse models predictive of antipsychotic activity","volume":"196","author":"Woolley","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.114.218651_bib57","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuropharm.2012.01.019","article-title":"CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [\u00b3H]LY459477 autoradiography","volume":"66","author":"Wright","year":"2013","journal-title":"Neuropharmacology"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524188830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524188830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.114.218651","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T17:55:46Z","timestamp":1739987746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524188830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0022356524188830"],"URL":"https:\/\/doi.org\/10.1124\/jpet.114.218651","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurophysiologic and Antipsychotic Profiles of TASP0433864, a Novel Positive Allosteric Modulator of Metabotropic Glutamate 2 Receptor","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.114.218651","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}